NCT04963153 2026-03-18
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
3 trialsNCT05567185 2026-03-13
TAR-210
Janssen Pharmaceutical K.K.
Phase 1 Active not recruiting
NCT03547037 2025-04-28
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers
Janssen Pharmaceutical K.K.
Phase 1 Completed